TABLE 6. Summary of meningococcal vaccines available in Canada.

Name of product	Type of vaccine	Manufacturer	Concentration of polysaccharide(s)	Protein carrier	Administration	Manufacturer’s Schedule
Quadrivalent Meningococcal Vaccines (conjugate and polysaccharide):
Menactra™	Conjugate A, C, Y, W-135	sanofi pasteur	4 μg of each serogroup	48 μg of diphtheria toxoid	0.5 ml IM	2 to 55 years of age – one dose
Menveo™	Conjugate A, C, Y, W-135	Novartis	10 μg of serogroup A 5 μg of each of serogroups C, W135 and Y	Varying amounts of CRM197 Conjugated to each polysaccharide	0.5 ml IM Requires reconstitution	2 to 55 years of age – one dose
Menomune™ A/C/Y/W-135	Polysaccharide A, C, Y, W-135	sanofi pasteur	50 μg of each serogroup	Not applicable	0.5 ml SQ Requires reconstitution	Children 2 years of age and older, adolescents and adults – one dose; repeat at interval based on age if at ongoing risk; can be used for children 3 months of age and older for serogroup A protection
Monovalent Meningococcal C Conjugate Vaccines:
Meningitec™	Conjugate C	Pfizer Canada	10 μg	15 μg CRM197	0.5 ml IM	Infants 2–12 months of age – 2 doses starting no earlier than 2 months of age and separated by at least two months, with a booster dose in accordance with official recommendations, preferably at about 12 months of age;* Children 1 year of age and older, adolescents and adults – one dose
Menjugate®	Conjugate C	Novartis	10 μg	12.5 – 25 μg CRM197	0.5 ml IM Requires reconstitution	Infants 2–12 months of age – 3 doses starting no earlier than 2 months of age and separated by at least one month, with a booster dose in accordance with NACI recommendations;* Children 1 year of age and older, adolescents and adults – one dose
Neis Vac-C®	Conjugate C	Baxter (distributed by Glaxo SmithKline)	10 μg	10 – 20 μg tetanus toxoid	0.5 ml IM	Infants 2–12 months of age – 2 doses starting no earlier than 2 months of age and separated by at least two months, with one dose after 5 months of age; if primary series completed before 5 months of age give booster in second year of life approximately 1 year from last dose;* Children 1 year of age and older, adolescents and adults – one dose
IM – intramuscularly SQ – subcutaneously CRM197 Corynebacterium diphtheriae cross reacting material 197 *Note: For children receiving meningococcal C conjugate vaccines in infancy, NACI recommends an additional dose of meningococcal C conjugate vaccines in the second year of life (from 12 to 23 months of age) Note that NACI’s recommendations may differ from the manufacturer’s recommendations. NACI’s recommendations are outlined in the Canadian Immunization Guide and NACI meningococcal statements.